市場調查報告書

Dravet症候群(DS):市場洞察,到流行病學,及至2028年的市場預測

Dravet Syndrome - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 905933
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
Dravet症候群(DS):市場洞察,到流行病學,及至2028年的市場預測 Dravet Syndrome - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

本報告提供全球Dravet症候群(DS)的相關調查,疾病概要和流行病學,患者人口,主要9個國家(美國、德國、法國、義大利、西班牙、英國、奧地利、日本、澳洲)的市場分析,主要企業的產品等資訊。

目錄

第1章 重要的洞察

第2章 Dravet症候群市場概要

  • 2017年:市場佔有率(%)分佈
  • 2028年:市場佔有率(%)分佈

第3章 Dravet症候群:疾病的背景及概要

  • 簡介
  • 臨床性特徵
    • 癲癇
    • 認識
    • 異動症
    • 突然死
  • Dravet症候群的遺傳學
    • 鈉流通管道a1次單元遺傳基因(SCN1A)及王牌床症候群及相關
    • 電壓閘極鈉流通管道變異的功能性方面
    • SCN1A變異的檢測
    • 繼承方式及模式
    • 未伴有SCN1A的變化的Dravet症候群
  • 前兆及症狀
  • 病理生理學
  • 診斷
    • 鑑別診斷

第4章 流行病學及患者人口

  • 主要調查結果
  • 主要9個國家的Dravet症候群的總發生率

第5章 Dravet症候群的各國流行病學

第6章 美國

  • 假設及根據
  • Dravet症候群的事件人口
  • Dravet症候群相關的突然變異
    • 各級:突然變異的發生率
    • 各型:突然變異的發生率
  • 發作相關病例
  • 性別發生率
  • 各年齡發生率
  • 死亡率

第7章 歐洲5個國家

  • 假設及根據

第8章 德國

第9章 法國

第10章 義大利

第11章 西班牙

第12章 英國

第13章 奧地利

第14章 日本

第15章 澳洲

第16章 Dravet症候群的治療

  • 目前治療方法
    • 第1選擇療法:丙戊酸及Clobazam
    • 第2選擇療法
    • 第3選擇療法
  • 治療流程

第17章 潛在的需求

第18章 成藥

  • Diacomit:Biocodex
    • 藥的說明
    • 作用機制
    • 法規的里程碑
    • 優點及缺點
    • 安全性及有效性
    • 產品簡介
  • Epidiolex:GW Pharmaceuticals

第19章 新的治療方法

  • FINTEPLA:Zogenix
    • 產品說明
    • 其他發展活動
    • 法規的里程碑
    • 臨床開發
    • 安全性及有效性
    • 產品簡介

第20章 Dravet症候群:9個主要市場分析

  • 主要調查結果
  • 主要9個國家的總市場規模
  • 各治療線:主要9個國家的規模

第21章 各國市場預測

  • 美國:市場預測
  • 美國:市場規模
    • Dravet症候群的總市場規模
    • 各治療線(LoT):市場規模
  • EU-6各國:市場預測
  • 德國:市場規模
  • 法國:市場規模
  • 義大利:市場規模
  • 西班牙:市場規模
  • 英國:市場規模
  • 奧地利的市場規模
  • 日本:市場預測
  • 日本:市場規模

第22章 市場成長要素

第23章 市場障礙

第24章 附錄

第25章 調查方法

  • 所使用的醬汁(來源)

第26章 DelveInsight的服務內容

第27章 免責聲明

第28章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0506

DelveInsight's "Dravet Syndrome - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Dravet Syndrome, historical and forecasted epidemiology as well as the Dravet Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Dravet Syndrome market report provides current treatment practices, emerging drugs, Dravet Syndrome market share of the individual therapies, current and forecasted Dravet Syndrome market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Dravet Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Dravet Syndrome Disease Understanding and Treatment Algorithm

The DelveInsight Dravet Syndrome market report gives a thorough understanding of the Dravet Syndrome by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Dravet Syndrome.

Treatment

It covers the details of conventional and current medical therapies available in the Dravet Syndrome market for the treatment of the condition. It also provides Dravet Syndrome treatment algorithms and guidelines in the United States, Europe, and Japan.

Dravet Syndrome Epidemiology

The Dravet Syndrome epidemiology division provide insights about historical and current Dravet Syndrome patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Dravet Syndrome epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Dravet Syndrome Epidemiology

The epidemiology segment also provides the Dravet Syndrome epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Dravet Syndrome Drug Chapters

Drug chapter segment of the Dravet Syndrome report encloses the detailed analysis of Dravet Syndrome marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Dravet Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Dravet Syndrome treatment.

Dravet Syndrome Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Dravet Syndrome treatment.

Dravet Syndrome Market Outlook

The Dravet Syndrome market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Dravet Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Dravet Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Dravet Syndrome market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Dravet Syndrome market in 7MM.

The United States Market Outlook

This section provides the total Dravet Syndrome market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Dravet Syndrome market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Dravet Syndrome market size and market size by therapies in Japan is also mentioned.

Dravet Syndrome Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Dravet Syndrome market or expected to get launched in the market during the study period 2017-2030. The analysis covers Dravet Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Dravet Syndrome Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Dravet Syndrome key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Dravet Syndrome emerging therapies.

Reimbursement Scenario in Dravet Syndrome

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Dravet Syndrome domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Dravet Syndrome market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Dravet Syndrome Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Dravet Syndrome, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Dravet Syndrome epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Dravet Syndrome are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Dravet Syndrome market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Dravet Syndrome market

Report Highlights

  • In the coming years, Dravet Syndrome market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Dravet Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Dravet Syndrome. Launch of emerging therapies will significantly impact the Dravet Syndrome market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Dravet Syndrome
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Dravet Syndrome Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Dravet Syndrome Pipeline Analysis
  • Dravet Syndrome Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Dravet Syndrome Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Dravet Syndrome Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Dravet Syndrome Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Dravet Syndrome market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Dravet Syndrome total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Dravet Syndrome market size during the forecast period (2017-2030)?
  • At what CAGR, the Dravet Syndrome market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Dravet Syndrome market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Dravet Syndrome market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Dravet Syndrome?
  • What is the historical Dravet Syndrome patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Dravet Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Dravet Syndrome?
  • Out of all 7MM countries, which country would have the highest prevalent population of Dravet Syndrome during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Dravet Syndrome treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Dravet Syndrome in the USA, Europe, and Japan?
  • What are the Dravet Syndrome marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Dravet Syndrome?
  • How many therapies are developed by each company for Dravet Syndrome treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Dravet Syndrome treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Dravet Syndrome therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Dravet Syndrome and their status?
  • What are the key designations that have been granted for the emerging therapies for Dravet Syndrome?
  • What are the global historical and forecasted market of Dravet Syndrome?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Dravet Syndrome market
  • To understand the future market competition in the Dravet Syndrome market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Dravet Syndrome in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Dravet Syndrome market
  • To understand the future market competition in the Dravet Syndrome market

Table of Contents

1. Key Insights

2. Executive Summary of Dravet Syndrome

3. Competitive Intelligence Analysis for Dravet Syndrome

4. Dravet Syndrome: Market Overview at a Glance

  • 4.1. Dravet Syndrome Total Market Share (%) Distribution in 2017
  • 4.2. Dravet Syndrome Total Market Share (%) Distribution in 2030

5. Dravet Syndrome: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Dravet Syndrome Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Dravet Syndrome Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Dravet Syndrome Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Dravet Syndrome Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Dravet Syndrome Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Dravet Syndrome Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Dravet Syndrome Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Dravet Syndrome Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Dravet Syndrome Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Dravet Syndrome Treatment and Management
  • 8.2. Dravet Syndrome Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Dravet Syndrome Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Dravet Syndrome: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Dravet Syndrome Market Size in 7MM
  • 13.3. Dravet Syndrome Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Dravet Syndrome Total Market Size in the United States
    • 15.1.2. Dravet Syndrome Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Dravet Syndrome Total Market Size in Germany
    • 15.3.2. Dravet Syndrome Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Dravet Syndrome Total Market Size in France
    • 15.4.2. Dravet Syndrome Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Dravet Syndrome Total Market Size in Italy
    • 15.5.2. Dravet Syndrome Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Dravet Syndrome Total Market Size in Spain
    • 15.6.2. Dravet Syndrome Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Dravet Syndrome Total Market Size in the United Kingdom
    • 15.7.2. Dravet Syndrome Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Dravet Syndrome Total Market Size in Japan
    • 15.8.3. Dravet Syndrome Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Dravet Syndrome

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Dravet Syndrome Epidemiology (2017-2030)
  • Table 2 : 7MM Dravet Syndrome Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Dravet Syndrome Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Dravet Syndrome Epidemiology in Germany (2017-2030)
  • Table 6 : Dravet Syndrome Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Dravet Syndrome Epidemiology in France (2017-2030)
  • Table 8 : Dravet Syndrome Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Dravet Syndrome Epidemiology in Italy (2017-2030)
  • Table 10 : Dravet Syndrome Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Dravet Syndrome Epidemiology in Spain (2017-2030)
  • Table 12 : Dravet Syndrome Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Dravet Syndrome Epidemiology in the UK (2017-2030)
  • Table 14 : Dravet Syndrome Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Dravet Syndrome Epidemiology in Japan (2017-2030)
  • Table 16 : Dravet Syndrome Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Dravet Syndrome Epidemiology (2017-2030)
  • Figure 2 : 7MM Dravet Syndrome Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Dravet Syndrome Epidemiology in the United States (2017-2030)
  • Figure 4 : Dravet Syndrome Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Dravet Syndrome Epidemiology in Germany (2017-2030)
  • Figure 6 : Dravet Syndrome Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Dravet Syndrome Epidemiology in France (2017-2030)
  • Figure 8 : Dravet Syndrome Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Dravet Syndrome Epidemiology in Italy (2017-2030)
  • Figure 10 : Dravet Syndrome Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Dravet Syndrome Epidemiology in Spain (2017-2030)
  • Figure 12 : Dravet Syndrome Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Dravet Syndrome Epidemiology in the UK (2017-2030)
  • Figure 14 : Dravet Syndrome Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Dravet Syndrome Epidemiology in Japan (2017-2030)
  • Figure 16 : Dravet Syndrome Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)